Dexmedetomidine versus remifentanil in sedation, analgesia, and vital signs in stereotactic brain biopsy: A randomized, single-blind, active-controlled clinical trial

Faranak Behnaz, Parisa Sezari, Mohammad Mirahmadi Eraghi, Narges Bazgir, Sogol Asgari · 2026

Read Dexmedetomidine versus remifentanil in sedation, analgesia, and vital signs in stereotactic brain biopsy: A randomized, single-blind, active-controlled clinical trial by Faranak Behnaz, Parisa Sezari, Mohammad Mirahmadi Eraghi, Narges Bazgir, Sogol Asgari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13400931.txt.

Description

Faranak Behnaz and colleagues run, in 2026, a randomized trial comparing two sedation drugs during stereotactic brain biopsy, a needle procedure done through a fixed head frame. Dexmedetomidine calms patients while easing blood pressure and stress responses. Remifentanil is a very short-acting opioid. The trial weighed sedation depth, vital signs, pain and recovery.

One hundred forty patients were assigned to one drug or the other under single-blind conditions. The remifentanil group reached deeper sedation scores. The dexmedetomidine group kept higher heart rate and blood pressure readings during surgery. Afterward, that group reported less pain and needed significantly less morphine in recovery. The authors present a trade-off: deeper sedation with one drug, better pain control with the other.

Catalog record

CREATORFaranak Behnaz, Parisa Sezari, Mohammad Mirahmadi Eraghi, Narges Bazgir, Sogol Asgari
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE22732
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13400931

Browse the full library · About the Tower of Babel